Caterpillar handily beat Wall Street estimates — not for the first time
The construction manufacturer reported a 38% rise in sales in its construction industries arm.
Strong Bullish
84.6
What's Happening
Eli Lilly raised full-year sales guidance by $2 billion and hiked adjusted profit outlook on explosive Zepbound and Mounjaro demand, while Merck beat quarterly estimates on Keytruda strength and new product momentum. Both companies posted earnings that significantly exceeded consensus, signaling sustained pricing power and market share gains in high-margin therapeutic categories.
Market Impact
Lilly and Merck's outperformance validates the GLP-1 and immuno-oncology thesis that has driven pharma valuations higher. Investors are repricing risk downward for large-cap pharma exposed to obesity and cancer treatment markets, with both companies now guiding to stronger 2026 earnings despite macro headwinds. This reinforces sector rotation into defensive healthcare plays.
Broader Implications
The earnings beat confirms that secular tailwinds in obesity and oncology treatment are outpacing generic competition and pricing pressure. Lilly's $2 billion guidance raise signals confidence that Zepbound and Mounjaro can sustain double-digit growth even as competition from Novo Nordisk and others intensifies.
